Page 169 - 2021_10-Haematologica-web

Carfilzomib or bortezomib in first relapse MM
Response to treatment
Response at 24 weeks was available for 285 partici- pants. More participants receiving KCd achieved ≥VGPR compared to those receiving VCd (40.2% vs. 31.9%, for a difference of 8.3% [90% CI: -1.6, 18.2], non-inferior). In
logistic regression modeling of ≥VGPR at 24 weeks, the odds ratio was 1.48 (90% CI: 0.95, 2.31), demonstrating non-inferiority (Table 2A). Analysis of patient- and dis- ease-related factors showed broadly similar effects across subgroups (Figure 3A). The proportion of participants
Figure 2. CONSORT (Consolidated Standards of Reporting Trials) diagram. The patients’ flow through the study, according to randomization points and treatment arms. KCd: carfilzomib, cyclophosphamide, dexamethasone; VCd: bortezomib, cyclophosphamide, dexamethasone.
haematologica | 2021; 106(10)
2697